ProFibrix expands Management team and opens US subsidiary
New COO brings financing and product development experience in the US
Advertisement
ProFibrix B.V., a Dutch biotech company focused on products to stop bleeding and initiate tissue repair, announced that it has added Jan Ohrstrom, MD as COO to its Executive Management team. Dr. Ohrstrom was previously part of the Senior Management team that took ZymoGenetics Inc public, and played a key role in bringing Recombinant Human Thrombin to the US market. Dr. Ohrstrom will be based in Seattle, WA, where ProFibrix has established a wholly owned subsidiary. ProFibrix Inc. will facilitate the preparations of a global pivotal Phase II/III trial for the lead product FibrocapsTM, to be conducted in 2009/2010.
Dr. Jaap Koopman, Founder and CEO of ProFibrix said: “We are delighted with the decision of Dr. Ohrstrom to join ProFibrix. His extensive expertise in the management of drug development and business operations will be a tremendous asset to ProFibrix as we continue to move our products through clinical development towards commercialization and prepare for the next financing round early next year.”